Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E303 in Advanced Solid Tumors
NCT07524348Phase 1Recruiting
- Sponsor
- Samsung Bioepis
- Start
- Mar 2026
- Primary completion
- Jul 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of SBE303 in solid tumor, sponsored by Samsung Bioepis. Primary endpoints: Incidence of adverse events and serious adverse events at 3 years, Incidence of dose limiting toxicity and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
SBE303
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07524348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524348.